Article Type
Changed
Mon, 12/06/2021 - 18:41

Key clinical point: Mutations in a novel gene ANKRD36 were associated with disease progression in chronic myeloid leukemia (CML) and may help identify patients at risk of disease progression.

Major finding: Mutations in the ANKRD36 gene (c.1183_1184 delGC and c.1187_1188 dupTT) were exclusively found in all patients with CML in blast crisis (CML-BC) and accelerated phase (CML-AP) but not in those with chronic-phase CML (CML-CP) and healthy controls.

Study details: This study included 141 patients with either CML-CP (n = 123), CML-AP (n = 6), or CML-BC (n = 12) and 10 age- and gender-matched healthy controls.

Disclosures: This study was funded by the National Plan for Science, Technology and Innovation, King Abdul-Aziz City for Science and Technology, Kingdom of Saudi Arabia. The authors declared no conflict of interests.

 

Source: Iqbal Z et al. Biology. 2021;10(11):1182 (Nov 15). Doi: 10.3390/biology10111182.

Publications
Topics

Key clinical point: Mutations in a novel gene ANKRD36 were associated with disease progression in chronic myeloid leukemia (CML) and may help identify patients at risk of disease progression.

Major finding: Mutations in the ANKRD36 gene (c.1183_1184 delGC and c.1187_1188 dupTT) were exclusively found in all patients with CML in blast crisis (CML-BC) and accelerated phase (CML-AP) but not in those with chronic-phase CML (CML-CP) and healthy controls.

Study details: This study included 141 patients with either CML-CP (n = 123), CML-AP (n = 6), or CML-BC (n = 12) and 10 age- and gender-matched healthy controls.

Disclosures: This study was funded by the National Plan for Science, Technology and Innovation, King Abdul-Aziz City for Science and Technology, Kingdom of Saudi Arabia. The authors declared no conflict of interests.

 

Source: Iqbal Z et al. Biology. 2021;10(11):1182 (Nov 15). Doi: 10.3390/biology10111182.

Key clinical point: Mutations in a novel gene ANKRD36 were associated with disease progression in chronic myeloid leukemia (CML) and may help identify patients at risk of disease progression.

Major finding: Mutations in the ANKRD36 gene (c.1183_1184 delGC and c.1187_1188 dupTT) were exclusively found in all patients with CML in blast crisis (CML-BC) and accelerated phase (CML-AP) but not in those with chronic-phase CML (CML-CP) and healthy controls.

Study details: This study included 141 patients with either CML-CP (n = 123), CML-AP (n = 6), or CML-BC (n = 12) and 10 age- and gender-matched healthy controls.

Disclosures: This study was funded by the National Plan for Science, Technology and Innovation, King Abdul-Aziz City for Science and Technology, Kingdom of Saudi Arabia. The authors declared no conflict of interests.

 

Source: Iqbal Z et al. Biology. 2021;10(11):1182 (Nov 15). Doi: 10.3390/biology10111182.

Publications
Publications
Topics
Article Type
Disallow All Ads
Content Gating
No Gating (article Unlocked/Free)
Alternative CME
Disqus Comments
Default
Article Series
Clinical Edge Journal Scan: CML December 2021
Gate On Date
Sun, 10/24/2021 - 17:45
Un-Gate On Date
Sun, 10/24/2021 - 17:45
Use ProPublica
CFC Schedule Remove Status
Sun, 10/24/2021 - 17:45
Hide sidebar & use full width
render the right sidebar.
Conference Recap Checkbox
Not Conference Recap
Clinical Edge
Display the Slideshow in this Article
Medscape Article
Display survey writer
Reuters content
Disable Inline Native ads
WebMD Article